Rapid Micro Biosystems Q4 revenue rises 37% on higher Growth Direct system placements

Rapid Micro Biosystems

12/03/2026 11:09

Overview

U.S. life sciences automation firm's Q4 revenue rose 37% yr/yr to record high

Q4 net loss widened and missed analyst expectations

Company booked large multi-system orders from Amgen and Samsung Biologics

Outlook

Company expects 2026 revenue of $37 mln to $41 mln

Company sees 30 to 38 Growth Direct system placements in 2026

Company expects 2026 gross margin of about 20%

Result Drivers

PRODUCT SALES - Q4 product revenue rose 78% yr/yr, driven by increased Growth Direct system placements

LARGE ORDERS - Significant multi-system orders from Amgen in Q4 contributed to revenue growth

SERVICE REVENUE DECLINE - Q4 service revenue fell 34% yr/yr due to lower validation activity

Company press release: ID:nGNX9vlRrw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.28
Q4 Net Income
Miss
-$12.50 mln
-$10.30 mln (3 Analysts)
Q4 Operating Expenses
$11.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 82.6% above its March 11 closing price of $4.38

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)